Literature DB >> 29393380

Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis.

Suyang Yu1, Honglei Bian1, Xin Gao2, Lin Gui1.   

Abstract

Annexin A9 (ANXA9), a member of annexin family, has been reported be associated with colorectal cancer (CRC) carcinogenesis. However, the clinical significance of ANXA9 in CRC, particularly its correlation to invasion and metastasis remains ambiguous. The aim of the present study was to investigate the significance of ANXA9 in CRC and understand the molecular mechanism of ANXA9 in CRC invasion and metastasis. Expression levels of the ANXA9 protein in CRC tissues were detected using immunohistochemistry (IHC), and the clinical and prognostic value of ANXA9 was investigated. ANXA9‑siRNA was utilized to investigate the effect and molecular mechanism of ANXA9 in HCT116 cells. The IHC result demonstrated that the positivity rate of the ANXA9 protein in CRC tissue was significantly higher than that in adjacent mucosa (P<0.05), which was consistent with the western blot results. ANXA9 protein expression levels are associated with invasion depth and lymphatic metastasis. Furthermore, patients with ANXA9‑positive expression demonstrated a poor prognosis and ANXA9 was an independent risk factor for survival (P<0.05). After inhibiting ANXA9 in HCT116 cells, the activity and metastatic and invasion capacity of cells decreased significantly, and expression levels of ADAM metallopeptidase domain 17 and matrix metallopeptidase 9 were significantly downregulated, while the expression levels of tissue inhibitors of metalloproteinases‑1 and E‑cadherin were upregulated (P<0.05). Thus, positive ANXA9 expression may present as a novel marker for predicting poor prognosis in CRC patients, and ANXA9 may promote the invasion and metastasis of CRC by regulating invasion and metastasis‑associated genes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29393380     DOI: 10.3892/ijmm.2018.3432

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

1.  LOTUS: A single- and multitask machine learning algorithm for the prediction of cancer driver genes.

Authors:  Olivier Collier; Véronique Stoven; Jean-Philippe Vert
Journal:  PLoS Comput Biol       Date:  2019-09-30       Impact factor: 4.475

2.  Hsa-miR-105-1 Regulates Cisplatin-Resistance in Ovarian Carcinoma Cells by Targeting ANXA9.

Authors:  Xinxin Kou; Hui Ding; Lei Li; Hongtu Chao
Journal:  Anal Cell Pathol (Amst)       Date:  2021-02-24       Impact factor: 2.916

3.  ANXA9 as a novel prognostic biomarker associated with immune infiltrates in gastric cancer.

Authors:  Tongtong Zhang; Suyang Yu; Shipeng Zhao
Journal:  PeerJ       Date:  2021-12-15       Impact factor: 2.984

4.  ERα and ERβ Homodimers in the Same Cellular Context Regulate Distinct Transcriptomes and Functions.

Authors:  Dandan Song; Huan He; Rajitha Indukuri; Zhiqiang Huang; Lina Stepanauskaite; Indranil Sinha; Lars-Arne Haldosén; Chunyan Zhao; Cecilia Williams
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-06       Impact factor: 6.055

Review 5.  Pathobiological functions and clinical implications of annexin dysregulation in human cancers.

Authors:  Llara Prieto-Fernández; Sofía T Menéndez; María Otero-Rosales; Irene Montoro-Jiménez; Francisco Hermida-Prado; Juana M García-Pedrero; Saúl Álvarez-Teijeiro
Journal:  Front Cell Dev Biol       Date:  2022-09-28

6.  Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays.

Authors:  María González-González; José María Sayagués; Luis Muñoz-Bellvís; Carlos Eduardo Pedreira; Marcello L R de Campos; Jacinto García; José Antonio Alcázar; Patrick F Braz; Breno L Galves; Luis Miguel González; Oscar Bengoechea; María Del Mar Abad; Juan Jesús Cruz; Lorena Bellido; Emilio Fonseca; Paula Díez; Pablo Juanes-Velasco; Alicia Landeira-Viñuela; Quentin Lecrevisse; Enrique Montalvillo; Rafael Góngora; Oscar Blanco; José Manuel Sánchez-Santos; Joshua LaBaer; Alberto Orfao; Manuel Fuentes
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.